Placeholder Banner

BIO World Congress Announces 2017 GreenTech Investor Sessions

June 8, 2017

The Biotechnology Innovation Organization (BIO) today announced that eleven emerging companies will make formal presentations to investors during GreenTech Investor Sessions at the 2017 BIO World Congress on Industrial Biotechnology. The world’s largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Québec, Canada.

BIO’s GreenTech Investor Sessions provide emerging companies developing advanced biofuels and renewable chemical platforms to share their new technologies and value proposition through formal 15-minute presentations to an elite audience of investors and analysts. Companies were selected to present breakthrough clean technologies, bio-based consumer product strategies, proofs of concept, and extensive intellectual property coverage during the session.

The GreenTech Investor Sessions will take place on Monday July, 24:

8:30 AM:     DEINOVE

8:50 AM:     DMC Biotechnologies, Inc.

9:10 AM:     BOSK Bioproducts

10:35 AM:   S2G BioChemicals, Inc.

10:55 AM:   enEvolv

11:55 AM:   Lygos, Inc.

1:45 PM:     Mercurius Biorefining, Inc.

2:05 PM:     Kalion, Inc.

2:25 PM:     Leaf Resources, Ltd.

2:45 PM:     Industrial Microbes

3:05 PM:     Prospect Bio

 

All programs and sessions at the 2017 BIO World Congress on Industrial Biotechnology are open to members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

 

For more information on the conference please visit https://www.bio.org/events/bio-world-congress. For assistance, please contact worldcongress@bio.org.

Discover More
Action plan outlines the policies needed to ensure that the biotechnology sector remains a driving force for America’s health, prosperity, national security, and geopolitical strengthWASHINGTON (November 10, 2026) - The Biotechnology Innovation…
Complaint argues HHS and CMS exceeded statutory authority; rule puts patient access, investment in future innovation, and America’s long-term biotechnology leadership at risk.WASHINGTON, DC & SAN DIEGO, CA & SAN FRANCISCO, CA - The…
WASHINGTON, DC (October 28, 2026) – Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact…